Roth MKM Reiterates Buy on Panbela Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $25 price target for the company's stock.
December 18, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Panbela Therapeutics with a $25 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and maintenance of a $25 price target by a Roth MKM analyst suggests a strong conviction in the stock's potential. This could positively influence investor sentiment and potentially lead to a short-term increase in the stock price, especially if the market aligns with the analyst's perspective.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100